Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma

This trial is looking at the best second-line treatment options for people with stomach or gastroesophageal junction cancer that has spread or cannot be surgically removed. It is testing regimens that include albumin-bound paclitaxel (nab-paclitaxel), a chemotherapy drug that may cause fewer side effects than standard paclitaxel. **You may be eligible if...** - You are 18 to 80 years old - You have advanced stomach or gastroesophageal junction cancer confirmed by biopsy - Your cancer is HER2-negative - You have already received a first-line treatment with fluoropyrimidine plus platinum plus a PD-1/PD-L1 immunotherapy drug, and your cancer progressed - Your general health is reasonably good (ECOG score 0–2) - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have not yet had first-line treatment - Your cancer is HER2-positive - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.